 MENLO PARK, Calif., Aug. 16, 2021 GLOBE NEWSWIRE -- CohBar, Inc. NASDAQ: CWBR, a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the appointment of Carol Nast as an independent director on the companys Board, effective August 11, 2021. Ms. Nast has spent her career in executive level positions with both large multinational companies and early-stage companies in the medical industry. 